UK GPs to test for asthma using Pharmaxis’ Aridol
Thursday, 12 August, 2004
Having recently completed the Phase III clinical trials for its patented asthma prognostic, Aridol, Sydney-based Pharmaxis (ASX: PXS) today announced that the first patients had been enrolled in a major UK clinical study.
This will be the first in-field use of Aridol by GPs, and will allow comparisons between Aridol and existing diagnosis techniques used for asthma and chronic obstructive pulmonary disease. Some 16 per cent of people now diagnosed with asthma do not have the disease. The study will follow patients for 12 months and is expected to complete in 2006.
Pharmaxis, meanwhile, is analysing its Phase III data, a process expected to be completed by September. A positive outcome would allow the company to apply to Australian and European pharmaceutical regulatory agencies later this year for permission to begin marketing the test in 2005.
Nature helps to relieve physical pain
Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
